GoAI
Get started
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc.

GDRX

NASDAQHealthcareMedical - Healthcare Information Services

Open in GoAI

Previous close

$3.45

−$0.11 · -3.09%

Aug 21, 4:00 PM ET

GDRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

68

Undervalued

Momentum

46

Neutral

Sentiment

67

Bullish

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Wendy Barnes
Listed since
Sep 23, 2020
Employees
697

Market position

Day range

Current $3.45

52-week range

Current $3.45

Open
$3.60
Previous close
$3.56
Volume
1.75M
1.14× average
Average volume
1.53M
Average daily volume
Market cap
1.2B USD
Beta
1.58
Market reference 1
50-day average
$3.1162
+10.71% above average
200-day average
$2.6724
+29.10% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.25B USD
P/E (TTM)
65.59×
P/B (TTM)
1.81×
P/S (TTM)
1.52×
EV / EBITDA
6.76×
Earnings yield
3.15%
Free cash flow yield
17.02%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
88.05%
Operating margin
10.25%
Net margin
2.07%
Return on equity
4.94%
Return on assets
2.17%
Return on invested capital
4.03%

Financial health

Debt / equity
0.83×
Current ratio
2.61×
Altman Z-score
0.26
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends104%64%25%-14%Gross margin, FY2021: 93.73%Gross margin, FY2022: 91.51%Gross margin, FY2023: 91.08%Gross margin, FY2024: 93.91%Gross margin, FY2025: 92.77%Operating margin, FY2021: 1.80%Operating margin, FY2022: 0.23%Operating margin, FY2023: -3.60%Operating margin, FY2024: 8.31%Operating margin, FY2025: 10.98%Net margin, FY2021: -3.39%Net margin, FY2022: -4.28%Net margin, FY2023: -1.18%Net margin, FY2024: 2.07%Net margin, FY2025: 3.82%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 93.73%. Gross margin FY2022 91.51%. Gross margin FY2023 91.08%. Gross margin FY2024 93.91%. Gross margin FY2025 92.77%. Operating margin FY2021 1.80%. Operating margin FY2022 0.23%. Operating margin FY2023 -3.60%. Operating margin FY2024 8.31%. Operating margin FY2025 10.98%. Net margin FY2021 -3.39%. Net margin FY2022 -4.28%. Net margin FY2023 -1.18%. Net margin FY2024 2.07%. Net margin FY2025 3.82%.

Income trends

Revenue

796.85M USD+0.57%

Operating income

87.49M USD+32.87%

Net income

30.44M USD+85.72%
Income trends across reported periods879.82M USD547.95M USD216.08M USD−115.8M USDRevenue, FY2021: 745.42M USDRevenue, FY2022: 766.55M USDRevenue, FY2023: 750.27M USDRevenue, FY2024: 792.32M USDRevenue, FY2025: 796.85M USDOperating income, FY2021: 13.41M USDOperating income, FY2022: 1.74M USDOperating income, FY2023: −27.01M USDOperating income, FY2024: 65.85M USDOperating income, FY2025: 87.49M USDNet income, FY2021: −25.25M USDNet income, FY2022: −32.83M USDNet income, FY2023: −8.87M USDNet income, FY2024: 16.39M USDNet income, FY2025: 30.44M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 745.42M USD. Revenue FY2022 766.55M USD. Revenue FY2023 750.27M USD. Revenue FY2024 792.32M USD. Revenue FY2025 796.85M USD. Operating income FY2021 13.41M USD. Operating income FY2022 1.74M USD. Operating income FY2023 −27.01M USD. Operating income FY2024 65.85M USD. Operating income FY2025 87.49M USD. Net income FY2021 −25.25M USD. Net income FY2022 −32.83M USD. Net income FY2023 −8.87M USD. Net income FY2024 16.39M USD. Net income FY2025 30.44M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue796.85M USD792.32M USD750.27M USD766.55M USD745.42M USD
Cost of goods sold57.6M USD48.22M USD66.93M USD65.08M USD46.72M USD
Gross profit739.26M USD744.11M USD683.34M USD701.48M USD698.71M USD
Research and development121.03M USD123.75M USD135.84M USD143.14M USD125.86M USD
Selling, general, and administrative445.52M USD484.98M USD466.84M USD502.42M USD524.9M USD
Operating expenses651.76M USD678.26M USD710.35M USD699.74M USD685.3M USD
Interest income10.93M USD23.27M USD32.17M USD9.27M USD59K USD
Interest expense42.61M USD52.92M USD56.73M USD34.24M USD23.64M USD
Depreciation and amortization85.22M USD69.54M USD107.67M USD54.18M USD34.54M USD
Operating income87.49M USD65.85M USD−27.01M USD1.74M USD13.41M USD
Net income30.44M USD16.39M USD−8.87M USD−32.83M USD−25.25M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
9%
1 beat, 6 misses, 4 met estimates
Average EPS surprise
-5.82%
11 comparable reports
Latest EPS result
0.08
Estimate 0.08 · Beat by 0.40%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.140.110.090.06Q1 '25MissQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26MetQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.09, estimate 0.1, surprise -10.00%, Miss. Q2 2025, reported May 7, 2025: actual 0.09, estimate 0.09, surprise 0.00%, Met estimate. Q3 2025, reported Aug 6, 2025: actual 0.09, estimate 0.1, surprise -10.00%, Miss. Q4 2025, reported Nov 4, 2025: actual 0.08, estimate 0.09, surprise -11.11%, Miss. Q1 2026, reported Feb 25, 2026: actual 0.09, estimate 0.09, surprise 0.00%, Met estimate. Q2 2026, reported May 6, 2026: actual 0.07, estimate 0.07, surprise 0.00%, Met estimate. Q3 2026, reported Aug 5, 2026: actual 0.08, estimate 0.08, surprise +0.40%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates213.46M201.37M189.28M177.19MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 198.58M USD, estimate 199.73M USD, surprise -0.58%, Miss. Q2 2025, reported May 7, 2025: actual 202.97M USD, estimate 202.2M USD, surprise +0.38%, Beat. Q3 2025, reported Aug 6, 2025: actual 203.07M USD, estimate 205.25M USD, surprise -1.06%, Miss. Q4 2025, reported Nov 4, 2025: actual 196.03M USD, estimate 193.27M USD, surprise +1.43%, Beat. Q1 2026, reported Feb 25, 2026: actual 194.79M USD, estimate 193.27M USD, surprise +0.78%, Beat. Q2 2026, reported May 6, 2026: actual 194.01M USD, estimate 185.4M USD, surprise +4.64%, Beat. Q3 2026, reported Aug 5, 2026: actual 200.41M USD, estimate 193.23M USD, surprise +3.72%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 202.44M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.19

21.45% upside
Past 12 months12-month forecastHigh $5.00Average $4.19Low $3.75

Rating distribution

24 ratings
Strong buy00%
Buy938%
Hold1354%
Sell28%
Strong sell00%

Recent analyst actions

12 institutions

GDRX news

seekingalpha.com

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation…

Read source
youtube.com

Push for 'COMPETITIVE CASH PRICING': GoodRx CEO on TrumpRx partnership

GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness…

Read source
seekingalpha.com

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

GoodRx Q2 Earnings Call Highlights

GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses…

Read source
pymnts.com

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six…

Read source
zacks.com

GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

Read source

GDRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GDRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.99M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.25M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
3.13M
Weight
0.00%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
1.99M
Weight
0.00%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.61M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Dimensional - US Small Cap Value ETF logoDimensional - US Small Cap Value ETFDFSV
Market value
1.58M
Weight
0.02%
AUM
8.42B USD
Expense ratio
0.30%
Price / 1D
$40.29+0.72%
Dimensional - US Targeted Value ETF logoDimensional - US Targeted Value ETFDFAT
Market value
1.5M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.28%
Price / 1D
$71.67+0.67%
VictoryShares Small Cap Free Cash Flow ETF logoVictoryShares Small Cap Free Cash Flow ETFSFLO
Market value
882.58K
Weight
0.11%
AUM
778.53M USD
Expense ratio
0.56%
Price / 1D
$39.77+0.63%

Continue in GoAI

Research GDRX

research.disclaimer